Table 5 HPV-capsid antibodies in subgroups of HIV-positive men stratified by CD4 counts or high active antiretroviral therapy (HAART)
HPV antibodies | cumulative low risk (6, 11) | cumulative high risk (16, 18, 31) | |
|---|---|---|---|
CD4+ cells <200 /μl | (n = 42) | 8 (19,0%) | 17 (40,4%) |
CD4+ cells 200–400/μl | (n = 61) | 16 (26,2%) | 24 (39,3%) |
CD4+ cells <200 /μl | (n = 65) | 16 (24,6%) | 25 (38,4%) |
with HAART | (n = 96) | 26 (27,1%) | 42 (43,7%)* |
without HAART | (n = 72) | 14 (19,4%) | 24 (33,3%)* |